Drug discovery in pharmaceutical industry: productivity challenges and trends
作者： Ish Khanna
DOI: 10.1016/J.DRUDIS.2012.05.007
关键词:
摘要: Low productivity, rising R&D costs, dissipating proprietary products and dwindling pipelines are driving the pharmaceutical industry to unprecedented challenges scrutiny. In this article I reflect on current status of reasons for continued low productivity. An emerging 'symbiotic model innovation', that addresses underlying issues in drug failure attempts narrow gaps discovery processes, is discussed boost The emphasizes partnerships innovation deliver quality a cost-effective system. also discuss diverse options build balanced research portfolio with higher potential persistent delivery molecules.
elsevier.com
csmres.co.uk 参考文章(32)
Eric Bonabeau, Robert W. Armstrong, Neil Bodick, A more rational approach to new-product development. Harvard Business Review. ,vol. 86, pp. 96- ,(2008)
Asher Mullard, Could pharma open its drug freezers? Nature Reviews Drug Discovery. ,vol. 10, pp. 399- 400 ,(2011) , 10.1038/NRD3473
Nassim Nicholas Taleb, The Black Swan: The Impact of the Highly Improbable ,(2007)
Trinh L. Doan, Michael Pollastri, Michael A. Walters, Gunda I. Georg, The Future of Drug Repositioning: Old Drugs, New Opportunities Annual Reports in Medicinal Chemistry. ,vol. 46, pp. 385- 401 ,(2011) , 10.1016/B978-0-12-386009-5.00004-7
Ismail Kola, John Landis, Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. ,vol. 3, pp. 711- 716 ,(2004) , 10.1038/NRD1470
John L. LaMattina, The impact of mergers on pharmaceutical R&D Nature Reviews Drug Discovery. ,vol. 10, pp. 559- 560 ,(2011) , 10.1038/NRD3514
A.I. Graul, E. Cruces, The year's new drugs & biologics, 2010. Drugs of Today. ,vol. 47, pp. 27- 51 ,(2011) , 10.1358/DOT.2011.47.1.1587820
Nicholas A. Meanwell, Synopsis of some recent tactical application of bioisosteres in drug design. Journal of Medicinal Chemistry. ,vol. 54, pp. 2529- 2591 ,(2011) , 10.1021/JM1013693
Bernard Munos, Lessons from 60 years of pharmaceutical innovation Nature Reviews Drug Discovery. ,vol. 8, pp. 959- 968 ,(2009) , 10.1038/NRD2961
John Arrowsmith, Phase III and submission failures: 2007–2010 Nature Reviews Drug Discovery. ,vol. 10, pp. 87- 87 ,(2011) , 10.1038/NRD3375